tbuckley/cabot-search huggingface dataset:
Patient-Centered Medical Homes and Adherence to Chronic Disease Medications
Authors: Patrick Kearns
Journal: Annals of Internal Medicine (2017)

Letters16 May 2017Patient-Centered Medical Homes and Adherence to Chronic Disease MedicationsPatrick Kearns, MDPatrick Kearns, MDFrom Santa Clara Valley Medical Center, Los Gatos, California.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0157 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Lauffenburger and colleagues' study (1) explores the association between patient-centered medical homes (PCMHs) and medication adherence. They report that "the effect we observed was slightly smaller but may nevertheless be clinically meaningful." This study's retrospective cohort methodology does not allow a conclusion that differences observed were an effect of medical homes. The authors' references highlight the issue that PCMHs have not improved hard outcomes; however, process and surrogate outcomes do seem to improve. Their study adds 1 more process measure for evaluating the benefits of PCMHs. If medication adherence can improve, perhaps hard outcomes will also be ...References1. Lauffenburger JC, Shrank WH, Bitton A, Franklin JM, Glynn RJ, Krumme AA, et al. Association between patient-centered medical homes and adherence to chronic disease medications. Ann Intern Med. 2017;166:81-88. LinkGoogle Scholar2. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-30. [PMID: 15908846] CrossrefMedlineGoogle Scholar3. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-35. [PMID: 19528344] doi:10.1161/CIRCULATIONAHA.108.768986 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Santa Clara Valley Medical Center, Los Gatos, California.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0157. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAssociation Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications Julie C. Lauffenburger , William H. Shrank , Asaf Bitton , Jessica M. Franklin , Robert J. Glynn , Alexis A. Krumme , Olga S. Matlin , Edmund J. Pezalla , Claire M. Spettell , Gregory Brill , and Niteesh K. Choudhry Patient-Centered Medical Homes and Adherence to Chronic Disease Medications Julie C. Lauffenburger , Jessica M. Franklin , and Niteesh K. Choudhry Metrics Cited byFactors influencing poor medication adherence amongst patients with chronic disease in low-and-middle-income countries: A systematic scoping review 16 May 2017Volume 166, Issue 10Page: 760-761KeywordsAlgorithmsCohort studiesComputersDisclosureHealth careHealth statisticsMotivationRetrospective studies ePublished: 16 May 2017 Issue Published: 16 May 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Long Non-Coding RNA Induces De Novo Myelodysplastic Syndrome through Epigenetic Regulation
Authors: Maitri Shah, Valentina Pilecki, Roxana Redis, Linda Fabris, Maria Ciccone, Cristina Ivan, Ioana Berindan-Neago, Riccardo Fodde, Carlos E. Bueso-Ramos, Mihai Gagea, Guillermo Garcia Manero, George Calin
Journal: Blood (2015)
A network meta-analysis assessing the comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer.
Authors: Aiko Nagayama, Tetsu Hayashida, Koji Okabayashi, Hiromitsu Jinno, Maiko Takahashi, Tomoko Seki, Akiko Matsumoto, Takeshi Murata, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2013)

e11598 Background: The growing number of anti-HER2 agents suggests the eventual need for defining the optimal choice of neoadjuvant therapy for HER2-positive breast cancer. Multiple-treatments meta-analysis synthesizes information from a network of trials and combines direct and indirect evidence on the relative effectiveness. An indirect estimate of the benefit of A over B can be obtained by comparing trials of A v C with trials of B v C. In this study, we assessed the efficacy and safety of neoadjuvant therapy for HER2-positive breast cancer by conducting the direct and indirect comparisons from multiple RCTs. Methods: The primary outcome of the study was the number of the patients who achieved pathological complete response (pCR) defined as no invasive residual in breast or node. Secondary objectives were the number of patients who completed the treatment as planned and adverse events including diarrhea, neutropenia, cardiac events and skin disorder. Results: We identified 1047 articles by database search and 10 studies met our criteria. A total of 2247 patients in 7 different treatment arms were assessed; chemotherapy (CT) alone, CT with single or dual anti-HER2 agents and dual anti-HER2 agents without CT. Anti-HER2 agents evaluated were trastuzumab (T-mab), lapatinib, pertuzumab (P-mab). There was no significant difference between dual targeting treatment arms (CT + T-mab + lapatinib v CT + T-mab + P-mab, OR; 1.11, [0.42-2.86], p=0.41), however, lapatinib reduced the treatment completion mainly due to adverse events. Patients in dual targeting arms had significantly higher incidence of pCR than in other treatment arms. (CT + T-mab + P-mab v CT + T-mab, OR; 2.29, [1.02-5.02], p=0.02) Surface under the cumulative ranking probability curve (SUCRA) also indicated that CT + T-mab + P-mab had the highest probability of being the best treatment arm for pCR followed by CT + T-mab + lapatinib and CT + T-mab. Conclusions: This study provides evidence that combining two anti-HER2 agents with chemotherapy are the most effective treatment arms. Considering the cost and limited medical resources, CT + T-mab showed a well-balanced profile for efficacy, completion and safety.
Abstract #4315: In situ analysis of mucus by FTIR spectral imaging in colon adenocarcinomas: towards a potential tumor marker
Authors: Adrian Travo, Pierre Jeannesson, Rolf Wolthuis, Cyril Gobinet, Michel Manfait, Jacques Bara, Marie Forgue-Lafitte, Olivier Piot
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

FTIR spectral imaging (FTIR SI) is emerging as a promising tool for generating a reproducible spectral histology, based on the intrinsic biochemical composition of tissues. We previously reported that FTIR SI of colon carcinomas is highly efficient to reproduce histology directly from paraffin-embedded (PE) tissue sections without chemical dewaxing process and to provide relevant information on the intra-tumor heterogeneity that cannot be revealed by classical histology. Using a collection of human normal colon and colon adenocarcinomas, our study aimed at a further exploration of the possibilities of the FTIR SI approach for histological recognition, with a particular emphasis on secreted mucus. By referring to IR spectra originated from bovine purified mucins and human mucus extracted from begnin cysts, we show that secreted mucus of the tissue sections present the spectral fingerprint of mucin glycoproteins. This permitted an in situ localization of mucus-rich areas (secreted mucus, crypt foci) and of tissular structures devoid of mucus by constructing color-coded images using k-means clustering of spectral data. In addition, a clear distinction can be achieved between the apical and basal parts of mucus secreting cells, containing respectively high and low amount of intracellular mucus. To discriminate normal from adenocarcinoma colon tissues, a k-means subclustering was performed exclusively on secreted mucus spectra. These subclusters are present in both tissue types, without detectable spatial ordering and independently of the localization of the secreted mucus, i.e. lumen or center of the crypts in normal tissues and in aberrant crypts of adenocarcinomas. However, the samples present significant differences of subcluster percentages that can be used to discriminate normal (n=3) from tumoral (n=10) tissues. Analysis of mean spectra of the clusters highlighted variations in glycosylation, sialylation and amide bands between tissue types. These results reflect alterations in carbohydrate and sialic acid contents as well as changes in secondary structure of mucin core proteins between tissue types. Interestingly, k-means subclustering, performed on the restricted amide I and II bands, indicates that changes in mucin secondary structure represent the most relevant spectral marker of mucus to discriminate colon adenocarcinomas from normal tissue.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4315.
ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction:Executive Summary
Authors: Thomas J. Ryan, Jeffrey L. Anderson, Elliott M. Antman, Blaine A. Braniff, Neil H. Brooks, Robert M. Califf, L. David Hillis, Loren F. Hiratzka, Elliot Rapaport, Barbara J. Riegel, Richard O. Russell, Earl E. Smith, W. Douglas Weaver
Journal: Circulation (1996)

HomeCirculationVol. 94, No. 9ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction:Executive Summary
Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia
Authors: Christoph U. Correll, Jose M. Rubio, Gabriella Inczedy-Farkas, Michael L. Birnbaum, John M. Kane, Stefan Leucht
Journal: JAMA Psychiatry (2017)

Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing.To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia.Systematic search of PubMed and PsycInfo until May 13, 2016.Meta-analyses of randomized clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or nonantipsychotic medications vs placebos or antipsychotic monotherapy among adults with schizophrenia.Independent reviewers extracted the data and assessed the quality of the methods of the included meta-analyses using A Measurement Tool to Assess Systematic Reviews (AMSTAR), adding 6 new items to rate their quality. Effect sizes, expressed as standardized mean difference /Hedges g or risk ratio, were compared separately for combinations with any antipsychotic drug and for combinations with clozapine.The primary outcome was total symptom reduction. Secondary outcomes included positive and negative symptoms, treatment recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discontinuation of treatment because of any cause, and inefficacies or intolerabilities.Of 3397 publications, 29 meta-analyses testing 42 combination strategies in 381 individual trials and among 19 833 participants were included. For total symptom reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented clozapine were examined. Fourteen combination treatments outperformed controls (standard mean difference/Hedges g, -1.27 [95% CI, -2.35 to -0.19] to -0.23 [95% CI, -0.44 to -0.02]; P = .05). No combination strategies with clozapine outperformed controls. The quality of the methods of the meta-analyses was generally high (mean score, 9 of a maximum score of 11) but the quality of the meta-analyzed studies was low (mean score, 2.8 of a maximum score of 8). Treatment recommendations correlated with the effect size (correlation coefficient, 0.22; 95% CI, 0.35-0.10; P < .001), yet effect sizes were inversely correlated with study quality (correlation coefficient, -0.06; 95% CI, 0.01 to -0.12; P = .02).Meta-analyses of 21 interventions fully or partially recommended their use, with recommendations being positively correlated with the effect sizes of the pooled intervention. However, the effect sizes were inversely correlated with meta-analyzed study quality, reducing confidence in these recommendations. Higher-quality trials and patient-based meta-analyses are needed to determine whether subpopulations might benefit from combination treatment, as no single strategy can be recommended for patients with schizophrenia based on the current meta-analytic literature.
PWE-168 Omega-3 fatty acid infusion reduces gastrointestinal toxicity and prevents thromboembolism in patients with advanced oesophagogastric cancer treated with palliative platinum based chemotherapy: Abstract PWE-168 Table 1
Authors: AM Eltweri, A Thomas, A Dennison, M Metcalfe, D Bowrey
Journal: Gut (2015)

<h3>Introduction</h3> The omega-3 fatty acids, EPA and DHA have proven anticancer activity in laboratory and clinical cancer studies. This clinical trial evaluated whether adding omega-3 fatty acids to palliative platinum based chemotherapy influenced the outcome of patients with oesophagogastric cancer compared to those given chemotherapy alone <h3>Method</h3> 21 participants in the 1st stage of a phase II single arm trial received palliative chemotherapy, intravenous (IV) epirubicin (50mg/m<sup>2</sup>) and oxaliplatin (130mg/m<sup>2</sup>) every 21 days, oral capecitabine (1250mg/m<sup>2</sup>) daily for 21 days and IV omega-3 fatty acids (2ml/Kg/4 h) (Omegaven® Fresenius-Kabi). The Omegaven infusion was given immediately after the chemotherapy on days 1, 8 and 15 of each cycle (intervention). Clinical outcomes were compared to outcomes in 37 patients treated with chemotherapy alone (control). Toxicities were graded using the CTCAE v4.03. Clinical response rate was assessed by RECIST v1.1 criteria. <h3>Results</h3> Fifty-six patients eligible participants were screened for inclusion, 35 were excluded principally because of poor performance status. Twenty one patients were enrolled in the study, 20 received at least one treatment and they form the basis of this report. The radiological response and toxicity of the intervention and control groups are indicated (Table 1). The mean baseline and 7 day post treatment triglyceride levels were 1.7 mmol/l (95% CI 1.6- 1.79) and 1.66 mmol/l (95% CI 1.56–1.75) respectively. The highest recorded triglyceride level was 4.84 mmol/l. No patient experienced fat overload syndrome or grade 3/4 hypertriglyceridemia. Mean platelet counts were 217 X109/l in the intervention group (95% CI 207–226 X109/l) compared to 332 X109/l in the control group (95% CI 316–348 X109/l). <h3>Conclusion</h3> Compared to patients treated with chemotherapy alone, those treated with supplementary omega-3 fish oils had reduced chemotherapy related toxicity, notably fewer gastrointestinal and thromboembolic adverse effects. Omega-3 fatty acids have the potential to ameliorate the toxicity associated with chemotherapeutic agents. <h3>Disclosure of interest</h3> A. Eltweri Grant/ Research Support from: Fresenius-Kabi, A. Thomas Grant/ Research Support from: Fresenius-Kabi, A. Dennison Grant/ Research Support from: Fresenius-Kabi, M. Metcalfe Grant/ Research Support from: Fresenius-Kabi, D. Bowrey Grant/ Research Support from: Fresenius-Kabi, Nutricia
A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy
Authors: Dwight J. Rouse, Deborah G. Hirtz, Elizabeth Thom, Michael W. Varner, Catherine Y. Spong, Brian M. Mercer, Jay D. Iams, Ronald J. Wapner, Yoram Sorokin, James M. Alexander, Margaret Harper, John M. Thorp, Susan M. Ramin, Fergal D. Malone, Marshall Carpenter, Menachem Miodovnik, Atef Moawad, Mary J. O'Sullivan, Alan M. Peaceman, Gary D.V. Hankins, Oded Langer, Steve N. Caritis, James M. Roberts
Journal: New England Journal of Medicine (2008)

Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.
Models in Translational Oncology: A Public Resource Database for Preclinical Cancer Research
Authors: Claudia Galuschka, Rumyana Proynova, Benjamin Roth, Hellmut G. Augustin, Karin Müller-Decker
Journal: Cancer Research (2017)

The devastating diseases of human cancer are mimicked in basic and translational cancer research by a steadily increasing number of tumor models, a situation requiring a platform with standardized reports to share model data. Models in Translational Oncology (MiTO) database was developed as a unique Web platform aiming for a comprehensive overview of preclinical models covering genetically engineered organisms, models of transplantation, chemical/physical induction, or spontaneous development, reviewed here. MiTO serves data entry for metastasis profiles and interventions. Moreover, cell lines and animal lines including tool strains can be recorded. Hyperlinks for connection with other databases and file uploads as supplementary information are supported. Several communication tools are offered to facilitate exchange of information. Notably, intellectual property can be protected prior to publication by inventor-defined accessibility of any given model. Data recall is via a highly configurable keyword search. Genome editing is expected to result in changes of the spectrum of model organisms, a reason to open MiTO for species-independent data. Registered users may deposit own model fact sheets (FS). MiTO experts check them for plausibility. Independently, manually curated FS are provided to principle investigators for revision and publication. Importantly, noneditable versions of reviewed FS can be cited in peer-reviewed journals. Cancer Res; 77(10); 2557-63. ©2017 AACR.
Magnetic resonance imaging pallidal hypersignal in cirrhotic subjects
Authors: J Kulisevsky, J Pujol, J Deus, J Balanzó, A Pujol
Journal: Hepatology (1996)

in Alcoholism: Clinical and Experimental Research. 4 The 80 patients with biopsy-proven alcoholic liver disease were not We are writing in response to your letter pointing out the always diagnosed as alcohol dependent by psychiatrists.existence of overlaps in content in our articles published in However, 62 of 80 patients and 60 healthy controls were used HEPATOLOGY 1 and the Journal of Hepatology. 2 The letter for analysis in the Alcoholism: Clinical and Experimental showed that we submitted the data to two different journals Research paper.The reference 4 had to be added in the two using the same materials while assuring each journal that journals.the material was not under consideration elsewhere.IndeedWe intend, in our individual ways, to ensure that an incithere are areas of duplication in the papers.We have to apolodent like this will not occur a second time.gize for this lapse of professional ethics.We read your previous editorial thoroughly. 3 We did not understand well enough the limits of the materials we could analyze.Although this MASAYOSHI YAMAUCHI, M.D.
A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer
Authors: Wigard P. Kloosterman, Robert R.J. Coebergh van den Braak, Mark Pieterse, Markus J. van Roosmalen, Anieta M. Sieuwerts, Christina Stangl, Ronne Brunekreef, Zarina S. Lalmahomed, Salo Ooft, Anne van Galen, Marcel Smid, Armel Lefebvre, Fried Zwartkruis, John W.M. Martens, John A. Foekens, Katharina Biermann, Marco J. Koudijs, Jan N.M. Ijzermans, Emile E. Voest
Journal: Cancer Research (2017)

Abstract Genomic rearrangements that give rise to oncogenic gene fusions can offer actionable targets for cancer therapy. Here we present a systematic analysis of oncogenic gene fusions among a clinically well-characterized, prospectively collected set of 278 primary colon cancers spanning diverse tumor stages and clinical outcomes. Gene fusions and somatic genetic variations were identified in fresh frozen clinical specimens by Illumina RNA-sequencing, the STAR fusion gene detection pipeline, and GATK RNA-seq variant calling. We considered gene fusions to be pathogenically relevant when recurrent, producing divergent gene expression (outlier analysis), or as functionally important (e.g., kinase fusions). Overall, 2.5% of all specimens were defined as harboring a relevant gene fusion (kinase fusions 1.8%). Novel configurations of BRAF, NTRK3, and RET gene fusions resulting from chromosomal translocations were identified. An R-spondin fusion was found in only one tumor (0.35%), much less than an earlier reported frequency of 10% in colorectal cancers. We also found a novel fusion involving USP9X-ERAS formed by chromothripsis and leading to high expression of ERAS, a constitutively active RAS protein normally expressed only in embryonic stem cells. This USP9X–ERAS fusion appeared highly oncogenic on the basis of its ability to activate AKT signaling. Oncogenic fusions were identified only in lymph node–negative tumors that lacked BRAF or KRAS mutations. In summary, we identified several novel oncogenic gene fusions in colorectal cancer that may drive malignant development and offer new targets for personalized therapy. Cancer Res; 77(14); 3814–22. ©2017 AACR.
The Epstein-Barr virus-associated gastric carcinoma in Turkey.
Authors: Ilker Ozmen, Bulent Karagoz, Ismail Yilmaz, Irfan Kucuk, Gizem Narli, Hakan Terekeci, Yalcin Onem, Emrullah Solmazgul, Oguz Bilgi, Cihan Top
Journal: Journal of Clinical Oncology (2015)

e15107 Background: Epstein-Barr virus (EBV) causes gastric adenocarcinoma besides other etiologic factors. EBV prevalence among gastric cancers has been reported in several countries. EBV-positive gastric cancer frequency has not been known in Turkey. We aimed to investigate EBV positivity and describe associated clinicopathologic parameters in north-west region of Turkey. Methods: Eighty-five gastric cancer patients and 50 control patients with HP negative chronic gastritis were admitted to the study. Epstein–Barr virus-encoded small RNAs (EBER) in situ hybridization was used for EBV positivity. Results: ISH-EBER was positive in tumor tissues from 2 cancer patients. First EBER positive patient was a 56 years old-woman (in diagnose). Tumor was intermediate-differentiated intestinal type adenocarcinoma in antrum (T3N1M0). After adjuvant chemoradiotherapy, she has been followed up without relapse for over 9 years. Second patient was a 71 years-old man. T3N0M0 tumor was diffuse type, intermediate-differentiated adenocarcinoma in gastric corpus. He has been disease free for 3 years without adjuvant therapy. Conclusions: EBV-associated gastric carcinoma frequency is 2.4% in north-west region of Turkey. Future large studies which include other regions should be established in this population.
The global health law trilogy: towards a safer, healthier, and fairer world
Authors: Lawrence O Gostin, Mary Clare DeBartolo, Rebecca Katz
Journal: The Lancet (2017)

Global health advocates often turn to medicine and science for solutions to enduring health risks, but law is also a powerful tool. No state acting alone can ward off health threats that span borders, requiring international solutions. A trilogy of global health law-the Framework Convention on Tobacco Control, International Health Regulations (2005), and Pandemic Influenza Preparedness Framework-strives for a safer, healthier, and fairer world. Yet, these international agreements are not well understood, and contain gaps in scope and enforceability. Moreover, major health concerns remain largely unregulated at the international level, such as non-communicable diseases, mental health, and injuries. Here, we offer reforms for this global health law trilogy.